Why the study?
Does dapagliflozin affect the no-reflow phenomenon in patients with type 2 diabetes mellitus and acute myocardial infarction undergoing percutaneous coronary intervention?
Does dapagliflozin affect the no-reflow phenomenon in patients with type 2 diabetes mellitus and acute myocardial infarction undergoing percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
This letter to the editor discusses a study on the effect of dapagliflozin on the no-reflow phenomenon in patients with T2DM and acute myocardial infarction undergoing PCI.
To the Editor,We have read the article by Quisi et al. [1] which explored the effect of dapagliflozin on the noreflow phenomenon in patients with type 2 diabetes mellitus (T2DM) and acute myocardia...
No takes yet. Share an insight, caveat, or question.
Köseoğlu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: